KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Shares Outstanding (Weighted Average) (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $294.3 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Shares Outstanding (Weighted Average) rose 1.78% year-over-year to $294.3 million, compared with a TTM value of $294.3 million through Dec 2024, up 1.78%, and an annual FY2024 reading of $294.3 million, up 1.78% over the prior year.
  • Shares Outstanding (Weighted Average) was $294.3 million for Q4 2024 at AbCellera Biologics, up from $289.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $294.3 million in Q4 2024 and bottomed at $283.9 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 3 years is $287.6 million, with a median of $287.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 1.36% in 2023, then rose 1.78% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $285.1 million in 2022, then grew by 1.44% to $289.2 million in 2023, then increased by 1.78% to $294.3 million in 2024.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ABCL at $294.3 million in Q4 2024, $289.2 million in Q4 2023, and $289.5 million in Q3 2023.